ProShares Ultra Health Care is a leveraged exchange-traded fund designed to track the daily performance of the broader U.S. healthcare equity market. Currently, specific fundamental metrics such as the overarching sector and market capitalization are recorded as N/A in our database. The asset is trading at $46.16, having posted a 24-hour decline of 2.76% on a volume of 7,200 shares.

Based on our proprietary technical scoring system, the asset earns a total score of -3, generating a clear Sell rating. The dominant factor is the price dipping below the crucial 200-day Simple Moving Average ($46.28), penalizing the trend score by -2. Furthermore, the trend strength confirms this bearish bias: an ADX of 26.98 alongside a DMI- (33.49) that overpowers the DMI+ (25.89) indicates a strong downward trajectory (-1 point). Volume dynamics also favor sellers, as the On-Balance Volume (OBV) sits below its 5-day SMA, indicating ongoing distribution (-1 point). While the RSI remains strictly neutral at 44.58 (0 points), the MACD histogram provides a solitary bullish crossover (+1 point). However, this minor momentum shift fails to outweigh the broader negative trend.

Concluding with the broader context, aligning these technicals with fundamental data yields further caution. The asset shows a P/E ratio of 26.00 and an anomalous dividend yield reading of 164.0, which likely reflects unique fund distributions rather than standard corporate dividends. As an ETF, individual equity metrics like the latest reported EPS, earnings surprise percentages, and upcoming quarterly earnings dates are understandably unavailable (N/A). Without clear fundamental catalysts to reverse the ongoing price action, the prevailing bearish chart patterns dictate our outlook. Therefore, the technicals fully support our Sell rating.